Abstract
Hepatitis C virus (HCV) chronically infects 70 million people worldwide with an estimated annual disease-related mortality of 400,000. A vaccine could prevent spread of this pervasive human pathogen, but has proven difficult to develop, partly due to neutralizing antibody evasion mechanisms that are inherent features of the virus envelope glycoproteins, E1 and E2. A central actor is the E2 motif, hypervariable region 1 (HVR1), which protects several non-overlapping neutralization epitopes through an incompletely understood mechanism. Here, we show that introducing different HVR1-isolate sequences into cell-culture infectious JFH1-based H77 (genotype 1a) and J4 (genotype 1b) Core-NS2 recombinants can lead to severe viral attenuation. Culture adaptation of attenuated HVR1-swapped recombinants permitted us to identify E1/E2 substitutions at conserved positions both within and outside HVR1 that increased the infectivity of attenuated HVR1-swapped recombinants but were not adaptive for original recombinants. H77 recombinants with HVR1 from multiple other isolates consistently acquired substitutions at position 348 in E1 and position 385 in HVR1 of E2. Interestingly, HVR1-swapped J4 recombinants primarily acquired other substitutions: F291I (E1), F438V (E2), F447L/V/I (E2) and V710L (E2), indicating a different adaptation pathway. For H77 recombinants, the adaptive E1/E2 substitutions increased sensitivity to the neutralizing monoclonal antibodies AR3A and AR4A, whereas for J4 recombinants, they increased sensitivity to AR3A, while having no effect on sensitivity to AR4A. To evaluate effects of the substitutions on AR3A and AR4A binding, we performed ELISAs on extracted E1/E2 protein and performed immunoprecipitation of relevant viruses. However, extracted E1/E2 protein and immunoprecipitation of HCV particles only reproduced the neutralization phenotypes of the J4 recombinants. Finally, we found that the HVR1-swap E1/E2 substitutions decrease virus entry dependency on co-receptor SR-BI. Our study identifies E1/E2 positions that could be critical for intra-complex HVR1 interactions while emphasizing the need for developing novel tools for molecular studies of E1/E2 interactions.
Highlights
More than 70 million people are chronically infected with hepatitis C virus (HCV), and have an increased risk of developing liver cirrhosis and hepatocellular carcinoma
We describe substitutions at conserved envelope protein 1 (E1) and E2 positions both within and outside of hypervariable region 1 (HVR1) that appear critical for HVR1-specific E1/E2 function
Testing the effect of these substitutions on neutralizing antibodies (NAbs) binding to extracted protein and in Hepatitis C virus (HCV) immunoprecipitation we demonstrated the challenges of studying these phenomena outside the context of neutralization assays of infectious virus particles
Summary
More than 70 million people are chronically infected with hepatitis C virus (HCV), and have an increased risk of developing liver cirrhosis and hepatocellular carcinoma. Since 2011, direct-acting antivirals against HCV have greatly improved infection cure rates [2], but it is unlikely that global virus elimination can be achieved through treatment efforts alone. This is due to high drug cost and limited access to treatment, frequent undiagnosed infections, as well as emerging drug resistance and the risk of reinfection following treatment [3]. Vaccine development has proven difficult, partly because much remains unknown about the mechanisms of HCV evasion from neutralizing antibodies (NAbs) [4, 5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.